Plasma concentration of sDLL1 performed even better than the product of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor-binding protein-7 (TIMP2*IGFBP7, NephrocheckTM) that has already been approved for the prediction of AKI in critically ill patients (AUCROC: 0.74 in critically ill patients and 0.83 after cardiac surgery)27,32–35. This evidence concerns the gene TIMP2 and acute kidney injury.